OMass Therapeutics Welcomes Birgitte Volck as Non-Executive Director

OMass Therapeutics, a biotechnology leader in developing medicines for rare diseases, has appointed Dr. Birgitte Volck to its Board as a Non-Executive Director. Dr. Volck holds extensive experience in R&D and precision medicine, particularly in rare diseases, having held significant roles in top biotech firms. Her appointment comes as OMass prepares to advance its pipeline of therapeutics, including a promising MC2 receptor antagonist for congenital adrenal hyperplasia and Cushing's syndrome. This strategic board addition underscores the company's commitment to innovation in drug discovery leveraging its unique OdyssION platform. Syncona, a significant investor, supports this growth trajectory.